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Tandem High-Dose Chemotherapy and Autologous Stem Cell 
Transplantation in Young Children with Atypical Teratoid/
Rhabdoid Tumor of the Central Nervous System
The feasibility and effectiveness of tandem high-dose chemotherapy and autologous stem 
cell transplantation (HDCT/autoSCT) were evaluated in children younger than 3 yr of age 
with atypical teratoid/rhabdoid tumors (ATRT). Tandem HDCT/autoSCT was administered 
following six cycles of induction chemotherapy. Radiotherapy (RT) was administered if the 
tumor relapsed or progressed, otherwise, it was administered after 3 yr of age. Tumors 
relapsed or progressed during induction chemotherapy in 5 of 9 patients enrolled; 3 of 
these 5 received tandem HDCT/autoSCT as a salvage treatment. One patient died from 
sepsis during induction chemotherapy. The remaining 3 patients proceeded to tandem 
HDCT/autoSCT; however, 2 of these patients showed tumor relapse/progression after 
tandem HDCT/autoSCT. All 7 relapses/progressions occurred at primary sites even in 
patients with leptomeningeal seeding. Toxicities during tandem HDCT/autoSCT were 
manageable. A total of 5 patients were alive with a median follow-up of 20 (range 16-70) 
months from diagnosis. Four of 5 patients who received RT after relapse/progression are 
alive. The probability of overall survival at 3 yr from diagnosis was 53.3% ± 17.3%. Our 
tandem HDCT/autoSCT is feasible; however, early administration of RT prior to tandem 
HDCT/autoSCT should be considered to improve the outcome after tandem HDCT/autoSCT.
Key Words: Rhabdoid Tumor; Central Nervous System; Drug Therapy; Stem Cell 
Transplantation; Radiotherapy; Child
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INTRODUCTION
Central nervous system (CNS) atypical teratoid/rhabdoid tumor 
(ATRT) is highly malignant. ATRT accounts for 2%-3% of child-
hood CNS tumors, but up to 20% of malignant CNS tumors in 
patients younger than 3 yr of age (1, 2). The prognosis of ATRT 
is extremely poor because these tumors often rapidly relapse or 
progress despite aggressive surgery, conventional chemothera-
py, and/or irradiation (3, 4). Since Hilden et al. (1) created a reg-
istry for ATRT, the efficacy of many different treatments has been 
explored to improve the survival of ATRT patients (5-7). How-
ever, there has been no consensus as to the proper treatment 
strategy for ATRT.
  The very poor prognosis of ATRT in infants and young chil-
dren may be related to both the lower tolerance of younger pa-
tients for surgical procedures and to delays in diagnosis. Poor 
prognosis may be also related to the limited use of radiotherapy 
(RT) in very young children due to the risks of functional impair-
ment of the developing brain and late adverse effects including 
global reduction in IQ, cognitive deficits, and neuroendocrine 
dysfunctions (8-11). 
  Strategies using high-dose chemotherapy and autologous 
stem cell transplantation (HDCT/autoSCT) have been explored 
and indicate that these treatments might improve the prognosis Park ES, et al.  •  Tandem HDCT in Young Children with ATRT
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of high-risk pediatric solid tumors such as high-risk neuroblas-
toma and high-risk embryonal brain tumors (12-14). The results 
of clinical trials using HDCT/autoSCT for infants and young chil-
dren with malignant brain tumors also showed that it is possi-
ble to avoid or defer RT until 3 yr of age while maintaining or 
improving survival rates (15, 16). Recently, a few smaller studies 
suggested that tandem HDCT/autoSCT might be feasible for 
treating recurrent or high-risk brain tumors and might further 
improve outcomes (17, 18). In the present study, we evaluated 
the feasibility and effectiveness of tandem HDCT/autoSCT in 
children younger than 3 yr of age with ATRT. Our new treatment 
strategy aimed both to improve survival and to reduce risks for 
significant late adverse effects of RT.
MATERIALS AND METHODS
Patients
From July 2005, a phase I/II prospective study using tandem 
HDCT/autoSCT for very young children with malignant brain 
tumors was initiated by Korean Society of Pediatric Neuro-On-
cology. Children younger than 3 yr of age at diagnosis who were 
newly diagnosed with malignant brain tumors including ATRT 
were eligible for inclusion in the study. Low grade brain tumors 
including stem glioma were excluded from the study. The pri-
mary goal of the present study was to evaluate the feasibility of 
tandem HDCT/autoSCT in very young children with malignant 
brain tumors and the secondary goal was to evaluate whether 
tandem HDCT/autoSCT might improve survival of very young 
children with malignant brain tumors. The present study ana-
lyzed only patients with ATRT because ATRT has unique char-
acteristics compared to other brain tumors. 
  A pediatric neuropathologist who had no information about 
the children’s clinical courses, reviewed all cases. Loss of nucle-
ar expression of INI1 was confirmed by immunohistochemical 
staining. Disease extent at diagnosis was assessed using brain 
and spinal magnetic resonance imaging (MRI) and cerebrospi-
nal fluid (CSF) cytology. 
Induction treatment prior to HDCT/autoSCT
Surgery was the primary treatment for all resectable tumors. Six 
cycles of conventional chemotherapy were administered prior 
to tandem HDCT/autoSCT. Alternating CECV regimens (cispl-
atin 3 mg/kg once daily i.v. on day 0; etoposide 2.5 mg/kg once 
daily i.v. on days 0, 1, and 2; cyclophosphamide 50 mg/kg once 
daily i.v. on days 1 and 2; vincristine 0.05 mg/kg once daily i.v. 
on days 0 and 7) and CEIV regimens (carboplatin 10 mg/kg once 
daily i.v. on days 0 and 1; etoposide 2.5 mg/kg once daily i.v. for 
5 consecutive days from day 0; ifosfamide 50 mg/kg once daily 
i.v. for 5 consecutive days from day 0; vincristine 0.05 mg/kg once 
daily i.v. on days 0 and 7) were used. Induction chemotherapy 
cycles were scheduled to start 28 days apart, but some delays 
were permitted to allow absolute neutrophil count (ANC) and 
platelet count to recover to 1,000/μL and 100,000/μL, respective-
ly. Peripheral blood stem cells (PBSCs) were collected during 
the recovery phase of the first chemotherapy cycle. 
Salvage treatment after relapse/progression during 
induction chemotherapy
If the tumor relapsed or progressed during induction chemo-
therapy, second-look surgery was performed whenever possi-
ble. RT was also administered whenever second-look surgery 
was not possible or when a large residual tumor remained after 
second-look surgery. Otherwise, RT was administered after tan-
dem HDCT/autoSCT. Tandem HDCT/autoSCT was given if the 
tumor remained progression free during salvage treatment after 
first relapse/progression. 
Tandem HDCT/autoSCT
The CTE regimen (carboplatin 500 mg/m
2 once daily i.v. on days 
-8, -7, and -6; thiotepa 300 mg/m
2 once daily i.v. on days -5, -4, 
and -3; etoposide 250 mg/m
2 once daily i.v. on days -5, -4, and 
-3) and CM regimen (cyclophosphamide 1,500 mg/m
2 once dai-
ly i.v. on days -8, -7, -6, and -5; melphalan 60 mg/m
2 once daily 
i.v. on days -4, -3, and -2) were employed for the first and second 
HDCT/autoSCT, respectively. We allowed a 12-16 week interval 
between the first and second HDCT/autoSCT to prevent toxic 
death in the second HDCT/autoSCT. Roughly half of the PBSCs 
collected during a single leukapheresis round were infused for 
marrow rescue at each HDCT/autoSCT session. In patients who 
remained in complete response after tandem HDCT/autoSCT, 
RT was deferred until 3 yr of age unless the tumor relapsed.
Response and toxicity criteria
Disease response was evaluated by MRI and CSF cytology. Eval-
uations were repeated every two or three chemotherapy cycles 
prior to the first HDCT/autoSCT, between the first and second 
HDCT/autoSCT, every three months for the first year after the 
tandem HDCT/autoSCT, every four months for the second year 
after tandem HDCT/autoSCT, and then every six months there-
after. Tumor responses were categorized according to the Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) (19). Tox-
icities during HDCT/autoSCT were graded using the National 
Cancer Institute’s Common Toxicity Criteria (version 2.0). 
Statistics
Survival rates and event-free survival rate ± standard errors from 
diagnosis were estimated using the Kaplan-Meier method. An 
event was defined as the occurrence of a relapse, progression, 
or treatment-related death. Survival rates and progression-free 
survival rate ± standard errors from HDCT1 and RT were esti-
mated using the Kaplan-Meier method. Progressive disease was 
defined as greater than a 25% increase in tumor size or the ap-Park ES, et al.  •  Tandem HDCT in Young Children with ATRT
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pearance of a new area of tumor.
Ethics statement
The institutional review board of Keimyung University Hospital 
approved this study (IRB No.2005-12-009). All parents/guard-
ians gave their informed consent for this study.
RESULTS
Patient characteristics at diagnosis
Nine patients with ATRT were enrolled between September 
2005 and March 2010 from 5 institutions. Patient characteristics 
are listed in Table 1. The median age at diagnosis was 12 (range 
4-28) months. The tumor was located at the posterior fossa in 
five patients, supratentorially in three, and at the spinal cord in 
one. Four patients had significant residual tumors (> 1.5 cm
2) 
after initial surgery and six patients had leptomeningeal seeding.
Treatment prior to HDCT/autoSCT
Treatments and responses are listed in Table 1. Three patients 
(Patients 1, 5, and 9) proceeded to HDCT/autoSCT as scheduled 
without relapse/progression during induction chemotherapy (1 
complete response and 2 partial responses). Tumor relapse or 
progression during induction chemotherapy was seen in five 
patients (Patients 2, 3, 4, 6, and 7). All relapses/progressions oc-
curred at the primary tumor sites even in patients with lepto-
meningeal seeding. As salvage treatment, second-look surgery 
and/or RT were performed in four of the patients; the remain-
ing patient (Patient 6) died due to tumor progression before ini-
tiation of salvage treatment. Three of 4 patients who received 
salvage treatment remained progression free during salvage treat-
ment and could proceed to HDCT/autoSCT; however, the re-
maining patient (Patient 2) died due to tumor progression de-
spite second-look surgery and RT. One patient (Patient 8) died 
due to sepsis during induction chemotherapy. Otherwise, tox-
icities during induction chemotherapy were manageable with-
out significant organ dysfunction. The median number of CD34
+ 
cells collected during a median of 3 (range 1-4) leukapheresis 
events was 52.1 (range 11.1-205.1) × 10
6 cells/kg. 
Tandem HDCT/autoSCT 
A total of 6 patients (three without relapse/progression and three 
after relapse/progression) proceeded to HDCT/autoSCT (Table 
1). Tumor status prior to the first HDCT/autoSCT was complete 
response in two patients and partial response in four. The medi-
an age at the first HDCT/autoSCT was 20 (range 10-35) months. 
The median time from the first infusion of PBSCs to the initia-
Table 1. Patient characteristics
No.
Sex/Age  
at Dx
Location
Residual  
tumor 
> 1.5 cm
2
M  
stage
Summary of treatment
Tumor 
status at 
HDCT1
RT  
CSI/LRT  
(Gy)
Age  
at RT
Final outcome  
(follow-up from Dx)
1 F/4 m PF No  3 Sg – CTx6 – HDCT1 – HDCT2 – (PRG) PR ND ND 15 m (Dead), PRG at 13 m
2 F/6 m Spine Yes 3 Sg –CTx6 – (PRG) – Sg – RT -      0/54.0 12 m 7 m (Dead), PRG at 4 m
3 F/9 m PF Yes 3 Sg – CTx6 – (PRG) – Sg – HDCT1 – HDCT2  
– RT
PR 23.4/30.6 25 m 16 m+ (DF), PRG at 8 m
4  M/11 m PF No 0 Sg – CTx6 – (RL) – Sg – RT – HDCT1 – HDCT2 CR      0/30.0 20 m 50 m+ (DF), RL at 6 m
5   F/12 m PF No 0 Sg – CTx6 – HDCT1 – HDCT2 – (RL) – Sg  
– CTx2 – RT
CR 23.4/32.4 36 m 70 m+ (DF), RL at 21 m
6  M/13 m ST No 3 Sg – CTx2 – (PRG) - ND ND 2 m (Dead), PRG at 2 m
7  M/15 m PF No 1 Sg – CTx4 – (PRG) – Sg – RT – HDCT1  
– HDCT2 – (PRG) – CTx
PR 19.8/21.6 19 m 19 m+ (AWD), PRG at 4 m  
8   F/16 m ST Yes 0 Sg – CTx1 - ND ND 2 m, TRM (Sepsis)
9   F/28 m ST Yes 3 Sg – CTx6 – HDCT1 – HDCT2 – RT PR 23.4/30.6 40 m 20 m+ (DF)
Dx, diagnosis; HDCT1, first high-dose chemotherapy; HDCT2, second HDCT; CSI, craniospinal irradiation; LRT, local radiation therapy; PF, posterior fossa; ST, supratentorial; Sg, 
surgery; PRG, progression; RL, relapse; CR, complete response; PR, partial response; ND, not done; TRM, treatment-related mortality; AWD, alive with disease; DF, disease free.
Table 2. Type of grade 3 and 4 toxicity of tandem HDCT/autoSCT*
Parameters
HDCT1  
(n = 6)
HDCT2  
(n = 6)
Hematologic toxicity
   CD34
+ cells ( × 10
6/kg)
   Time (days) to reach an ANC 500/µL
‡
   Time (days) to reach a PLT count 20,000/µL
§
   Presence of high fever ≥ 38.5°C
   Days of high fever ≥ 38.5°C
   Documented infection
 
23.1 (5-42.6)
†
 9 (8-13)
 16 (10-35)
3
2 (0-2)
1
 
14.0 (3.4-47.8)
†
10 (9-12)
  26 (12-64)
2
0 (0-5)
3
Non-hematologic toxicity
   Stomatitis  
   Vomiting  
   Diarrhea  
   Elevation of liver enzyme  
   Hepatic veno-occlusive disease 
   Renal failure  
   Hypokalemia  
   Hyponatremia  
   Hypernatremia 
   Seizures
   Multi-organ failure
   Toxic death 
 
5
1
0
2
0
0
1
0
0
0
0
0
 
2
0
0
0
1
0
1
0
0
0
0
0
*Toxicities were graded according to the National Cancer Institute Common Toxicity 
Criteria (version 2.0); 
†Median (range); 
‡The first day when ANC exceeded 500/µL for 
3 consecutive days; 
§The first day when PLT count exceeded 20,000/µL without trans-
fusion for 7 days. HDCT1, first high-dose chemotherapy; HDCT2, second HDCT; ANC, 
absolute neutrophil count; PLT, platelet. Park ES, et al.  •  Tandem HDCT in Young Children with ATRT
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tion of the second HDCT was 95 (range 82-116) days. The char-
acteristics of tandem HDCT/autoSCT are shown in Table 2. Time 
to obtain ANC > 500/μL in each HDCT was 9 (8-13) days and 
10 (9-12) days and time to platelet > 20,000/μL was 16 (10-35) 
days and 26 (12-24) days, respectively. Frequent grade 3/4 tox-
icities during tandem HDCT/autoSCT were stomatitis and fever. 
Frequencies of grade 3/4 toxicities were not higher in the second 
HDCT/autoSCT compared to the first HDCT/autoSCT. Toxici-
ties were manageable and there was no treatment-related death 
during tandem HDCT/autoSCT. 
Radiation therapy
In summary, 6 patients received RT (Table 1). Only one received 
RT after HDCT/autoSCT as planned and 5 received RT as sal-
vage treatment after relapse/progression. The median age at ini-
tiation of RT was 22 (range 12-40) months and 5 patients received 
RT before 3 yr of age and 2 of whom are alive with disease free. 
Radiation dosage of these two patients was craniospinal 23.4 
Gy/local 30.6 Gy, and local 30 Gy only. Four patients received 
both craniospinal and local RT, and 2 patients received local RT 
alone. Neuro-cognitive functions of lived patients were not yet 
evaluated.
Survival
Tumors relapsed or progressed in seven patients (five during in-
duction chemotherapy and two after tandem HDCT/autoSCT). 
Four of the seven patients are still alive after salvage treatment. 
One patient died from sepsis during induction chemotherapy. 
Only one patient remained progression free after diagnosis. 
Therefore, a total of five patients are alive with a median follow-
up of 20 (range 16-70) months from diagnosis. The probabilities 
of overall survival and event-free survival at 3 yr from diagnosis 
were 53.3% ± 17.3% and 0%, respectively (Fig. 1A). Five of six 
patients who received tandem HDCT/autoSCT are alive with a 
median follow-up of 13 (range 7-64) months from the first HDCT/ 
autoSCT. The probabilities of overall survival and progression-
free survival at 3 yr from the first HDCT/autoSCT were 80.0% ±  
17.9% and 31.2% ± 24.5%, respectively (Fig. 1B). Five of 6 patients 
who received RT are alive with a median follow-up of 14 (range 
2-46) months from the initiation of RT. The probabilities of over-
all survival and progression-free survival at 3 yr from the initia-
tion of RT were 80% ± 17.9% and 53.3% ± 24.8%, respectively 
(Fig. 1C).
DISCUSSION
Unacceptable adverse effects of RT, particularly craniospinal RT, 
for very young children with brain tumors has led a number of 
institutions and national groups to adopt chemotherapy-based 
strategies designed to avoid or delay RT (20-22). Actually cure 
has been documented in several cases even in the absence of 
RT (1, 23). In a phase I study using novel chemotherapy regimen 
including thiotepa, carboplatin, and carmustine for recurrent 
brain tumor in children, two patients with relapsed ATRT were 
reported to remain alive longer than 7 yr after HDCT/autoSCT 
(24). These data suggested that HDCT has significant activity 
Fig. 1. A total of five patients are alive with a median follow-up of 20 (range 16-70) 
months from diagnosis. The probabilities of overall survival (OS) and event-free sur-
vival (EFS) at 3 yr from diagnosis were 53.3% ± 17.3% and 0%, respectively (A). The 
probabilities of overall survival and progression-free survival (PFS) at 3 yr from the 
first HDCT/autoSCT were 80.0% ± 17.9% and 31.2% ± 24.5%, respectively (B). The 
probabilities of overall survival and progression-free survival at 3 yr from the initiation 
of RT were 80.0% ± 17.9% and 53.3% ± 24.8%, respectively (C).
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against ATRT. In the present study, we evaluated the feasibility 
and effectiveness of tandem HDCT/autoSCT in very young chil-
dren with ATRT, aiming to improve survival and to avoid or de-
fer RT until after the most radiosensitive neurodevelopmental 
mileposts. To our knowledge, the present study is the first trial 
employing the tandem HDCT/autoSCT strategy for very young 
children with ATRT. 
  ATRT was very rare and previously misdiagnosed as other 
CNS embryonal tumors such as primitive neuro-ectodermal 
tumor or germ cell tumor. However, recently diagnostic confirm 
was possible using diverse immunohistochemical staining and 
detecting INI1 gene loss. The majority of rhabdoid tumor arises 
as a result of homozygous inactivating deletions or mutations 
of the INI1 gene located in chromosome band 22q11.2 (25).  
  In our small cohort, tumors progressed or relapsed in seven 
of nine patients. Interestingly, all relapses/progressions occurred 
at primary sites even in patients with leptomeningeal seeding. 
However, four of five patients who received RT after relapse/pro-
gression are still alive. Recent studies have showed that RT might 
be more efficacious than chemotherapy for ATRT patients, even 
for very young children (3, 26). Chi et al. (27) recently reported 
encouraging results of a single arm trial for newly diagnosed 
ATRT patients, in which local RT was administered during the 
early treatment period irrespective of age. Taken together, these 
findings suggest that RT is effective in ATRT and that early ad-
ministration of RT, at least local RT, might prevent early relapse/
progression during induction chemotherapy, resulting in im-
proved outcomes.
  In our study, only 3 patients completed induction chemother-
apy and could proceed to tandem HDCT/autoSCT as sched-
uled without relapse/progression. These findings suggest that 
our induction chemotherapy regimen might be ineffective for 
preventing tumor relapse/progression. A few investigators have 
described long-term survivors who had received RT and che-
motherapy which had been used for the treatment of rhabdo-
myosarcoma patients (6, 7, 27). Taken together, a novel chemo-
therapy regimen as well as early administration of RT is needed 
to improve outcomes in the treatment of ATRT.
  Recently, Rosenfeld et al. (28) reported the feasibility of tan-
dem HDCT/autoSCT in patients with brain tumors. They used 
the same tandem HDCT regimen (CTE/CM) as ours. Two of 19 
patients who received the first HDCT/autoSCT and 4 of 11 pa-
tients who received the second HDCT/autoSCT died of toxicity. 
The authors concluded that the CTE/CM regimen is not feasible 
due to toxicity. On the contrary, toxicities in our present study 
were manageable and transient, and no toxic death occurred. 
The only difference between the two studies was the interval be-
tween the first and second HDCT/autoSCT. While the second 
HDCT began by day 50 with an ANC > 1,000/μL and resolutions 
of all significant toxicities in the study by Rosenfeld et al. (28), we 
allowed a 12-16 week interval between the first and second 
HDCT/autoSCT as a cautionary measure of potential toxicity 
during the second HDCT/autoSCT. We previously reported that 
a shorter interval (< 12 weeks) between the first and second 
HDCT/autoSCT might be associated with higher toxic death 
rate in the second HDCT/autoSCT (29). Taken together, our tan-
dem HDCT protocol is relatively safe if patients have sufficient 
rest between the first and second HDCT/autoSCT. 
  A total of six patients received tandem HDCT/autoSCT, and 
three of them received tandem HDCT/autoSCT as a salvage 
treatment after relapse/progression. Although three patients 
remained progression free after tandem HDCT/autoSCT, the 
effectiveness of tandem HDCT/autoSCT is unclear, because all 
survivors received RT as well as tandem HDCT/autoSCT. 
  In summary, our tandem HDCT/autoSCT is feasible; howev-
er, early administration of RT prior to tandem HDCT/autoSCT 
should be considered to improve the outcome after tandem 
HDCT/autoSCT even in very young patients.
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